Myeloma Australia is committed to keeping the Australian myeloma community informed about any new treatment submissions to be considered by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC decides which medicines will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) in Australia.
For the prevention of skeletal related events in multiple myeloma, the monoclonal antibody, denosumab is being considered for approval at the upcoming July meeting.
Denosumab presents a new treatment option for many patients for the prevention of myeloma related bone disease and it can be used in myeloma patients regardless of their renal status as it is not cleared by the kidneys. Denosumab has recently been approved in the USA and Europe by their respective regulatory authorities.
The PBAC are calling for consumer comments which provides the opportunity for the myeloma community to submit feedback about the importance of another myeloma treatment being available through the PBS. Myeloma Australia’s advocacy team will submit comments on behalf of the organisation as a voice of the myeloma community.
Comments are open until the 6th of June
- Online http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form
- Mail- PBAC Secretariat, MDP 952, Department of Health and Ageing, GPO Box 9848, ACT, 2601
- Fax – 02 6289 4175. Attention PBAC Secretariat
Please don’t hesitate to contact Myeloma Australia (1800 693 566) if you have any questions.